Skip to main content
. Author manuscript; available in PMC: 2017 Jun 26.
Published in final edited form as: Mol Cancer Ther. 2010 Jul 6;9(7):2026–2036. doi: 10.1158/1535-7163.MCT-10-0238

Figure 5.

Figure 5

Degrasyn and bortezomib synergy is associated with NF-κB and STAT3 inhibition, concurrent with down-regulation of the cell growth and survival genes cyclin D1 and c-Myc in MCL cells. (A) Mino cells were treated with bortezomib (BZ; 10 nM) alone, degrasyn (1 μM) alone, or a combination of the two. After 24 and 48 h, nuclear extracts from the cells were purified and subjected to STAT DNA-binding enzyme-linked immunosorbent assay. The data shown are the means and ranges of triplicate samples of three independent experiments. Error bars represent standard deviation. (B) Nuclear extracts from part (A) above were also examined by EMSA for NF-κB DNA binding. Cont, control; BZ, bortezomib; DG, degrasyn. (C) Nuclear extracts from part (A) were Western blotted for c-Myc, cyclin D1, and Oct-1 (loading control) protein expression. Cont, control; BZ, bortezomib; DG, degrasyn. (D) Mino cells were treated with bortezomib (BZ; 10 nM) alone, degrasyn (1 μM) alone, or a combination of the two. After 24 h, RNA from cells was purified and real-time PCR was performed for c-myc and cyclin D1. Relative mRNA expressions were normalized with GAPDH and Oct-1. The data shown are the means and ranges of triplicate samples of two independent experiments. Error bars represent standard deviation.